La Jolla Pharmaceutical has signed up to a deal with HealthCare Royalty Partners, giving the pharma $125 million in financing in return for tiered royalty payments on worldwide sales of Giapreza. The money will help the company push the shock drug onto the market.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,